New drug trial targets recurring brain tumors
NCT ID NCT06970145
Summary
This study is testing whether the drug anlotinib can help control recurrent craniopharyngioma, a type of brain tumor that has come back after previous treatment. It will enroll about 57 adults to see if the drug shrinks tumors, delays tumor growth, and is safe to use. The trial is open-label, meaning all participants receive the drug, and researchers will track tumor size, survival time, and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRANIOPHARYNGIOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Southern Medical University, Nanfang Hospital, Department of Neurosurgery
RECRUITINGGuangzhou, Guangdong, 510515, China
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.